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Scientific confirmation of the benefit of implantable
cardioverter-defibrillators (ICDs) has been a slowly evolving
process. Approximately 16 years elapsed between the first
placement of an ICD in a patient and the publication of the
Multicenter Automatic Defibrillator Implantation Trial
(MADIT), the first randomized primary prevention trial of
ICDs versus conventional antiarrhythmic therapy (1). Dur-
ing that interval, opinion-based practice patterns for ICD
use emerged, anchored to the rationale of the concept, the
futility of other therapies in high risk patients, uncontrolled
observational studies and historical expectations. The
MADIT was designed to generate evidence of benefit for a
very specific high risk subgroup of post-myocardial infarc-
tion patients, and the results demonstrated a 54% reduction
of all-cause mortality in the ICD-treated patients as com-
pared with those treated with conventional therapy. That
outcome provided evidence-based confirmation of the va-
lidity of one of the practice patterns.
After another year passed, the results of the Antiarrhyth-
mics Versus Implantable Defibrillators (AVID) trial were
published (2). AVID was the first randomized trial of ICDs
versus drug therapy in survivors of cardiac arrest or hemo-
dynamically significant ventricular tachyarrhythmias (2).
Again, the ICD-treated group had improved survival, ex-
periencing a 27% relative risk reduction at two years of
follow up. It was followed shortly by reports from two other
trials—the Canadian Implantable Defibrillator Study
(CIDS) and the Cardiac Arrest Study of Hamburg
(CASH), neither of which are published yet.
Because the ICD performed better than drug therapy for
the patient groups in both MADIT and AVID, and the
results of CIDS and CASH did not contradict AVID, the
outcomes of these trials have established the ICD as
preferred therapy for the patient groups included in the
studies (3). However, there are still many unanswered
questions, and the persisting uncertainties about extrapola-
tion of the data from these studies to other patient groups
remains a challenge to clinical decision-making. Very re-
cently, data from the Multicenter UnSustained Tachycardia
Trial (MUSTT) was presented at a national meeting (4).
Although the final report has not yet been published, the
data presented suggest that the observations in that trial will
support the reported outcome of MADIT. Its limitation is
that it does not take us much further than a similar, specific
high risk subgroup of patients in which ICDs are superior to
drug therapy.
With the primary outcomes of the completed trials in
hand, investigators are now evaluating subtleties within the
data bases of these trials, and additional insights are begin-
ning to emerge. In this issue of the Journal of the American
College of Cardiology, the report of a subgroup analysis of the
AVID population takes us a step further (5). The data
suggest that the cumulative outcome data from AVID
contain subgroup behavior that may be important for the
clinician applying the information from the AVID trial to
clinical practice. The cumulative data had demonstrated a
27% reduction in mortality at two years of follow-up among
a group of patients with a mean ejection fraction of ’32%
(2). However, the subgroup analysis suggests that patients
with ejection fractions in the range of 35% to 40% derived
no added benefit from ICD therapy as compared with drug
therapy. All of the ICD-attributed benefit occurred among
patients with ejection fractions ,35%. It is also pointed out
that the subgroup of patients whose ejection fractions were
,20% did not achieve a statistically significant benefit from
ICD therapy. The absolute and, to a lesser extent, the
relative outcome differences were similar to those observed
in groups with ejection fractions in the range of 20% to 34%.
The confounding problem was the small number of patients
enrolled with ejection fractions ,20%. Therefore, the ICD
benefit for that subgroup should be considered inconclusive
rather than ineffective. More data are needed, and for now
clinical decisions for patients with ejection fractions ,20%
should be driven by physician–patient deliberations, rather
than these limited data.
See pages 1082 and 1090
Subgroup behavior within large clinical trials is becoming
increasingly recognized as a factor that impacts upon the
practical influence of the reported intervention (6). The
equivalence of outcome of ICD and drug therapy in the 35%
to 40% ejection fraction subgroup does not negate the
possibility that both therapies provide benefit. As a positive
control trial (comparing two active therapies), the only
conclusion possible is that the influence of both is the
same—whether it is beneficial, neutral or harmful (6).
Without a placebo arm in the study, the distinction is
impossible. Although the subgroup analysis of the AVID
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data has conceptual value and supports a rationale for
adequate stratification in study design, it leaves the physi-
cian with another practical problem. Given the subjective
nature of ejection fraction estimates in clinical practice, and
accepting the notion that individual estimates average out in
a large trial, the actual clinical application of this relevant
observation will be difficult.
Another study reported in this issue of the Journal of the
American College of Cardiology (7) was intended to determine
the outcome of patients with syncope in the presence of
coronary artery disease who received an ICD on the basis of
the results of invasive electrophysiologic diagnostic study
procedures. The investigators observed that electrophysi-
ologic testing yielded a possible mechanism of syncope in
48% of the patients studied (32 of 67 patients), including 29
with tachyarrhythmic mechanisms and three with brady-
arrhythmic mechanisms. Patients with inducible tachycar-
dias had a much worse outcome over a two-year follow-up
period than did those who could not be induced into a
ventricular tachyarrhythmia. The question of risk and out-
come is important because other studies, in different patient
groups, have also suggested that patients with advanced
structural heart disease and syncope have a poor outcome
(8).
The risk data observed in this report are of interest, but
the ICD-related outcomes have to be interpreted cautiously.
The report is from a nonrandomized observational study,
further limited by a small number of patients. Because only
those patients who could be induced into a ventricular
tachyarrhythmia despite intravenous procainamide therapy
received an ICD, and none of the patients who were
noninducible received ICDs, no valid conclusions can be
drawn about the potential mortality benefit of ICDs in
either patient subgroup. It is clear from the authors’ data
that patients who are inducible are at very high risk of
dying—55% actuarial at two years and 33% cumulative. It is
conjectural whether the risk might have been even higher in
a group of patients with inducible tachycardias who were
randomized to drug therapy. Moreover, those patients in
whom tachyarrhythmias were not induced still had a sub-
stantial mortality risk (16% actuarial at two years; 18%
cumulative), even though it was lower than that in the
patients in whom tachycardias were induced. Even they
could conceivably have benefited from ICD therapy if a
benign cause of syncope is excluded. Curiously, it appears
that .50% of those with a negative electrophysiologic study
did not undergo tilt testing, leaving unanswered questions
about the nature of that subgroup.
The authors express disappointment because of their
observation that patients with inducible ventricular tachy-
arrhythmias had a very high mortality rate, despite having
received ICDs (7). However, the group characteristics—
mean ejection fraction of 32%, previous myocardial infarc-
tion in 76% and inducible/nonsuppressible ventricular
tachyarrhythmias during electrophysiologic study—define a
group in which a very high mortality risk is expected (1).
Does clinical syncope add more to the expected risk?
Perhaps so, but that point is not proved by the data
provided.
Although the mortality rate is so high as to question ICD
efficacy in that study group, few would argue against ICD
therapy for such patients on the basis of reasonable clinical
judgment, even without proof of efficacy. Only a controlled
trial—one that is not likely to be done—could answer that
question. In contrast, if the AVID substudy report can be
extrapolated to the interpretation of this study (5,7)—a risky
statistical exercise—one might conclude, a priori, that the
group with inducible arrhythmias (mean 6 SD ejection
fraction 5 32 6 11%) would benefit and the group without
inducible arrhythmias (mean 6 SD ejection fraction 5
41 6 12%) would not. A study of greater interest would be
a comparison between patients with and without inducible
tachycardias after syncopal events, stratified by ejection
fraction. Thus, the major contribution in this study is the
observation that among patients with coronary artery dis-
ease who have syncope, a meaningful proportion can be
induced into ventricular tachyarrhythmias, an observation
that is predicted at least in part by ejection fraction and in
turn predicts a poor outcome.
The observations in both reports addressing issues in
ICD therapy in this issue of the Journal of the American
College of Cardiology (5,7) confirm the notion that the
existing published clinical trials on ICD therapy, which is an
expensive but potentially life-saving strategy, are difficult to
generalize. This concern applies to attempts to extend
beyond the limits defined by a given study group (1,7), and
even within the population boundaries (2,5). The American
Heart Association/American College of Cardiology/North
American Society of Pacing and Electrophysiology (AHA/
ACC/NASPE) consensus statement on indications for
ICD therapy (9) is helpful for providing general guidelines
for indications (class I), uncertainties (class II) and circum-
stances in which devices are not indicated (class III).
Refinement of criteria ultimately will lead to stronger
statements of justification for use of ICDs in appropriate
patients, counterbalanced by clarification of those clinical
circumstances in which the devices do not provide benefit.
As we await information from other ongoing trials, such as
Sudden Cardiac Death in Heart Failure Trial of prophylac-
tic amiodarone versus implantable defibrillator therapy
(SCD-HeFT) and MADIT-2, the rational clinical applica-
tion of this therapy will undergo opinion-based adjust-
ments, based on judgments derived from the cumulative
data provided in the published reports. Clearly, the need for
additional clinical trials in this area of therapeutics has not
expired.
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